Extracellular acidification and hyperkalemia induce changes in HERG inhibition by ibutilide

Cardiology

Volumn 110, Issue 3, 2008, Pages 209-216

  Lin, Congrong ^a   Ke, Xiaogang ^a   Ranade, Vasant ^a   Somberg, John ^a,b  

^a RUSH UNIVERSITY MEDICAL CENTER   (United States)

^b RUSH UNIVERSITY   (United States)

Author keywords

Acidosis; HERG channel; Hyperkalemia; Ibutilide

Indexed keywords

IBUTILIDE; POTASSIUM CHANNEL HERG; POTASSIUM CHLORIDE;

ACIDIFICATION; ANIMAL CELL; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; FEMALE; HYPERKALEMIA; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; VOLTAGE CLAMP;

ANIMALS; ANTI-ARRHYTHMIA AGENTS; DELAYED RECTIFIER POTASSIUM CHANNELS; DOSE-RESPONSE RELATIONSHIP, DRUG; ETHER-A-GO-GO POTASSIUM CHANNELS; FEMALE; HYDROGEN-ION CONCENTRATION; MEMBRANE POTENTIALS; OOCYTES; PATCH-CLAMP TECHNIQUES; POTASSIUM; SULFONAMIDES; XENOPUS LAEVIS;

EID: 44849126141     PISSN: 00086312     EISSN: None     Source Type: Journal    
DOI: 10.1159/000111932     Document Type: Article

References (35)

1. Shah RR: Drug-induced QT interval prolongation - regulatory guidance and perspectives on hERG channel studies. Novartis Found Symp 2005;266:251-280.
2. Keating MT, Sanguinetti MC: Molecular and cellular mechanisms of cardiac arrhythmias. Cell 2001;104:569-580.
3. Sanguinetti MC, Jiang C, Curran ME, Keating MT: A mechanistic link between an inherited and an acquired cardiac arrhythmia: HERG encodes the I Kr potassium channel. Cell 1995;81:299-307.
4. Trudeau MC, Warmke JW, Ganetzky B, Robertson GA: HERG, a human inward rectifier in the voltage-gated potassium channel family. Science 1995;269:92-95.
5. Yang T, Snyders D, Roden DM: Drug block of I(kr): model systems and relevance to human arrhythmias. J Cardiovasc Pharmacol 2001;38:737-744.
6. Roden DM: Drug-induced prolongation of the QT interval. N Engl J Med 2004;350:1013-1022.
7. Hester JB, Gibson JK, Cimini MG, Emmert DE, Locker PK, Perricone SC, Skaletzky LL, Sykes JK, West BE: N-[(omega-amino-1-hydroxyalkyl)phenyl] methanesulfonamide derivatives with class III antiarrhythmic activity. J Med Chem 1991;34:308-315.
8. Roden DM: Ibutilide and the treatment of atrial arrhythmias. A new drug - almost unheralded - is now available to US physicians. Circulation 1996;94:1499-1502.
9. + channel, IKr, and effects on myocardial refractoriness for class III antiarrhythmic agents. J Cardiovasc Pharmacol 1995;25:336-340.
10. Kr) in AT-1 cells: concentration-, time-, voltage-, and use-dependent effects. Circulation 1995;91:1799-1806.
11. Naccarelli GV, Lee KS, Gibson JK, Vander-Lugt J: Electrophysiology and pharmacology of ibutilide. Am J Cardiol 1996;78:12-16.
12. Ellenbogen KA, Clemo HF, Stambler BS, Wood MA, VanderLugt JT: Efficacy of ibutilide for termination of atrial fibrillation and flutter. Am J Cardiol 1996;78:42-45.
13. Stambler BS, Wood MA, Ellenbogen KA, Perry KT, Wakefield LK, VanderLugt JT: Efficacy and safety of repeated intravenous doses of ibutilide for rapid conversion of atrial flutter or fibrillation. Ibutilide Repeat Dose Study Investigators. Circulation 1996;94:1613-1621.
14. Lin C, Ke X, Cvetanovic I, Ranade V, Somberg J: The influence of extracellular acidosis on the effect of IKr blockers. J Cardiovasc Pharmacol Ther 2005;10:67-76.
15. Lin C, Ke X, Cvetanovic I, Ranade V, Somberg J: The effect of high extracellular potassium on IKr inhibition by anti-arrhythmic agents. Cardiology 2006;108:18-27.
16. Singarayar S, Bursill J, Wyse K, et al: Extracellular acidosis modulates drug block of Kv4.3 currents by flecainide and quinidine. J Cardiovasc Electrophysiol 2003;14:641-650.
17. Mergenthaler J, Haverkamp W, Huttenhofer A, et al: Blocking effects of the antiarrhythmic drug propafenone on the HERG potassium channel. Naunyn Schmiedebergs Arch Pharmacol 2001;363:472-480.
18. Khuri SF, Healey NA, Hossain M, et al: Intraoperative regional myocardial acidosis and reduction in long-term survival after cardiac surgery. J Thorac Cardiovasc Surg 2005;129:372-381.
19. Gettes LS, Hill JL, Saito T, Kagiyama Y: Factors related to vulnerability to arrhythmias in acute myocardial infarction. Am Heart J 1982;103:667-672.
20. Wilde AA, Escande D, Schumacher CA, Thuringer D, Mestre M, Fiolet JW, Janse MJ: Potassium accumulation in the globally ischemic mammalian heart. A role for the ATP-sensitive potassium channel. Circ Res 1990;67:835-843.
21. Watanabe I, Johnson TA, Buchanan J, Engle CL, Gettes LS: Effect of graded coronary flow reduction on ionic, electrical, and mechanical indexes of ischemia in the pig. Circulation 1987;76:1127-1134.
22. Pelleg A, Mitamura H, Price R, Kaplinsky E, Menduke H, Dreifus LS, Michelson EL: Extracellular potassium ion dynamics and ventricular arrhythmias in the canine heart. J Am Coll Cardiol 1989;13:941-950.
23. Johnson TA, Engle CL, Boyd LM, Koch GG, Gwinn M, Gettes LS: Magnitude and time course of extracellular potassium inhomogeneities during acute ischemia in pigs. Effect of verapamil. Circulation 1991;83:622-634.
24. Cobbbe SM, Manley BS: Effects of elevated extracellular potassium concentrations on the class III antiarrhythmic action of sotalol. Cardiovasc Res 1985;19:69-75.
25. Marschang H, Beyer T, Karolyi L, Kubler W, Brachmann J: Differential rate and potassium-dependent effects of the class III agents d-sotalol and dofetilide on guinea pig papillary muscle. Cardiovasc Drugs Ther 1998;12:573-583.
26. Baskin EP, Lynch JJ Jr: Comparative effects of increased extracellular potassium and pacing frequency on the class III activities of methanesulfonanilide IKr blockers dofetilide, D-sotalol, E-4031, and MK-499. J Cardiovasc Pharmacol 1994;24:199-208.
27. Haverkamp W, Breithardt G, Camm AJ, Janse MJ, Rosen MR, Antzelevitch C, Escande D, Franz M, Malik M, Moss A, Shah R: The potential for QT prolongation and proarrhythmia by non-antiarrhythmic drugs: clinical and regulatory implications. Report on a policy conference of the European Society of Cardiology. Eur Heart J 2000;21:1216-1231.
28. Al-Dashti R, Sami M: Dofetilide: a new class III antiarrhythmic agent. Can J Cardiol 2001;17:63-67.
29. Vaughan Williams EM, Somberg J: Control of Cardiac Rhythm. Philadelphia, Lippincott-Raven, 1998, p 51.
30. Hohnloser SH: Proarrhythmia with class III antiarrhythmic drugs: types, risks, and management. Am J Cardiol 1997;80:82G-89G.
31. Podrid PJ: Proarrhythmia, a serious complication of antiarrhythmic drugs. Curr Cardiol Rep 1999;1:289-296.
32. Garlick PB, Radda GK, Seeley PJ: Studies of acidosis in the ischaemic heart by phosphorus nuclear magnetic resonance. Biochem J 1979;184:547-554.
33. Khuri SF, Flaherty JT, O'Riordan JB, et al: Changes in intramyocardial ST segment voltage and gas tensions with regional myocardial ischemia in the dog. Circ Res 1975;37:455-463.
34. Coraboeuf E, Deroubaix E, Hoerter J: Control of ionic permeabilities in normal and ischemic heart. Circ Res 1976;38(5 suppl 1):I92-I98.
35. Orchard CH, Cingolani HE: Acidosis and arrhythmias in cardiac muscle. Cardiovasc Res 1994;28: 312-1319.